Reinduction Therapy for Advanced Colorectal Cancer
Author Information
Author(s): M Hejna, GV Kornek, M Raderer, D Depisch, T Brodowicz, WCC Fiebiger, W Scheithauer
Primary Institution: University Medical School, Vienna
Hypothesis
The study aims to investigate the therapeutic value of reinduction therapy with the same cytostatic treatment used for induction in patients with metastatic colorectal cancer.
Conclusion
Reinduction therapy with the same regimen is an acceptable treatment option for patients with advanced colorectal cancer who have previously responded to treatment.
Supporting Evidence
- Among 49 evaluable patients, reinduction therapy resulted in a 69% overall tumor control rate.
- The median time to treatment failure from reinduction was 6.4 months.
- The median survival duration from reinduction was 8.9 months.
- Nine patients had a partial response after reinduction, yielding an overall response rate of 18%.
- Patients with prior complete or partial response had a median survival time of 23.8 months.
Takeaway
Doctors tested if giving the same cancer treatment again after a break could help patients with advanced colorectal cancer. It worked for some patients and was safe.
Methodology
This was a prospective evaluation of patients who had achieved a response or stable disease after first-line chemotherapy and were treated with the same regimen upon relapse.
Potential Biases
The study population was closely monitored, which may not reflect a general patient population.
Limitations
Only 49 out of 112 patients were eligible for analysis due to various exclusion criteria.
Participant Demographics
The median age of participants was 65.5 years, with 28 males and 21 females.
Statistical Information
P-Value
0.33
Confidence Interval
95% CI 54.6-81.7%
Statistical Significance
p=0.33
Want to read the original?
Access the complete publication on the publisher's website